Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
Curigliano G, Dent R, Llombart-Cussac A, Pegram M, Pusztai L, Turner N, Viale G. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer. Npj Breast Cancer 2023, 9: 56. PMID: 37380659, PMCID: PMC10307886, DOI: 10.1038/s41523-023-00560-z.Peer-Reviewed Original ResearchOptimal treatment pathwayBreast cancerCyclin D kinase 4/6 inhibitorDifferent adjuvant treatment modalitiesFuture risk stratification strategiesSimilar prognostic accuracyAdjuvant treatment modalitiesEarly breast cancerRisk of recurrenceRisk stratification strategiesRisk prediction toolsIndividual patient levelEpidermal growth factor receptorBreast cancer diagnosisGrowth factor receptorTreatment guidelinesRisk stratificationMultigene assaysTreatment modalitiesClinical trialsPatient levelPrognostic accuracyTreatment pathwaysEarly breast cancer diagnosisLevel I